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Abstract
Purpose of Review By all measures, the morbidity and mor-
tality due to dengue are continuing to worsen worldwide.
Although both early and recent studies have demonstrated
regional differences in how dengue affects local populations,
these findings were to varying extents related to disparate
surveillance approaches.
Recent Findings Recent studies have broadened the recog-
nized spectrum of disease resulting from DENV infection,
particularly in adults, and have also demonstrated new mech-
anisms of DENV spread both within and between popula-
tions. New results regarding the frequency and duration of
homo- and heterotypic anti-DENV antibodies have provided
important insights relevant to vaccine design and
implementation.
Summary These observations and findings as well as difficulties
in comparing the epidemiology of dengue within and between
regions of the world underscore the need for population-based
dengue surveillance worldwide. Enhanced surveillance should
be implemented to complement passive surveillance in countries
in the tropics to establish baseline data in order to define affected
populations and evaluate the impact of dengue vaccines and
novel vector control interventions.
Keywords Dengue . Epidemiology . Burden
Introduction
As is true for many emerging infectious diseases, increasing
global circulation of dengue is a result of the expansion and
urbanization of society [1]. The four genetically and antigen-
ically distinct dengue virus (DENV) types [2•] diverged from
a common ancestor roughly 1000 years ago [3]. Each virus
independently shifted from a mosquito-monkey-mosquito cy-
cle of transmission to becoming endemic in humans several
hundred years ago [3, 4]. The advent of maritime transporta-
tion enabled the dispersal of Aedes mosquitoes and DENV-
infected humans throughout the tropics, and dengue outbreaks
were increasingly reported during the seventeenth century [3].
World War II played a prominent role in enabling co-
circulation of multiple DENV types and subsequent epi-
demics of dengue hemorrhagic fever (DHF) in Southeast
Asia in the 1950s [5]. Aedesmosquitoes were nearly eradicat-
ed from the Americas in the middle of the twentieth century
[6]. However, unsustainable vector control strategies [7]
allowed the resurgence of Aedes mosquito populations in the
Americas, and epidemics of DHF were first reported through-
out the region in the 1980s [8]. Thus, the global spread and
increasing severity of dengue were enabled by increased pop-
ulation growth, more frequent and expansive international
travel, and societal urbanization that produced more abundant
mosquito breeding sites (e.g., refuse, discarded tires, septic
tanks) [9].
The four DENV types and their mosquito vectors are now
present throughout the tropics and sub-tropics worldwide (Fig. 1)
[10, 11]. Recent dengue incidence has increased greatly [8], hav-
ing roughly doubled each decade since 1990 [12]. Though both
annual incidence andmethods utilized to estimate incidence vary,
recent estimates have suggested that 96 million dengue cases
occurred in 2010 [13] and 58 million dengue cases and over
9000 deaths occurred in 2013 [14•]. Longitudinal analysis of
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surveillance data from Southeast Asia [15] and the Americas [8]
demonstrated longer and more frequent dengue epidemics and
increasing dengue-related morbidity and mortality. By all mea-
sures, the worldwide economic and health-associated burden of
dengue has increased dramatically since World War II, and this
trendwill likely continue until an effective dengue vaccine and/or
sustainable control strategy is identified to prevent DENV trans-
mission [16].
As such prevention and control strategies are implemented,
measuring their effect will be critical to demonstrate efficacy
in preventing disease and saving lives. Findings from evalua-
tions can be used to develop recommendations regarding best
practices in controlling dengue. Doing so will require a com-
prehensive understanding of the epidemiology of dengue, in-
cluding the populations most affected, spectrum of clinical
disease, and temporal and spatial patterns of illness. Despite
several decades of study, many misperceptions regarding the
epidemiology of dengue persist among the public, clinicians,
and public health professionals. These misperceptions have
occurred in part because much of our early knowledge of
dengue was gained during the first DHF epidemics in
Southeast Asia. Understanding of these epidemics was limited
by a lack of population-based case identification and/or labo-
ratory diagnostics to distinguish dengue from other causes of
acute febrile illness (AFI). Specifically, many early studies of
dengue in Southeast Asia were performed solely among hos-
pitalized children suspected to have dengue [17]. As a result,
dengue hemorrhagic fever (and hence, by proxy, dengue) was
perceived to be an illness exclusively of childhood. Still other
studies were conducted in dengue-naïve adults (i.e., soldiers)
sent overseas to Asia [18]. Consequently, our initial under-
standing of dengue came from populations that were not rep-
resentative of the entire population living in areas with endem-
ic dengue.
This review calls attention to new findings on the epidemi-
ology of dengue worldwide with respect to previous percep-
tions. In particular, these new findings include improved rec-
ognition of the spectrum of disease caused by DENV infec-
tion, particularly in adults, the mechanisms of DENV dissem-
ination within populations, and the role of homo- and hetero-
typic anti-DENV antibodies in affecting DENV transmission
in populations. We discuss whether these findings are due to
increased clinical awareness, improved surveillance and diag-
nostics, demographic changes, or actual epidemiological
shifts in affected populations. We provide an epidemiologic
framework hopefully useful to further improve our under-
standing of dengue epidemiology, and we detail the additional
steps needed to gain a more complete understanding of the
epidemiology of dengue worldwide.
Improved Recognition of DENV Infection as a Cause
of Acute Febrile Illness
For decades, dengue has been perceived as a clinical syn-
drome defined by fever, body aches, leukopenia, and other
symptoms of acute viral infection [19, 20]. Also recognized
Fig. 1 Regions of the world where there is available evidence for risk of dengue virus infection. Map provided by CDC Travelers’ Health Branch. For
up-to-date information on dengue activity, please see dengue map (www.healthmap.org/dengue)
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for several decades is the potentially fatal DHF/dengue shock
syndrome associated with bleeding manifestations, capillary
leakage, and elevated hematocrit. However, DENV infection
can result in a variety of outcomes ranging from asymptomatic
infection, to mild or sub-clinical illness, to hospitalization and
death with other clinical presentations. Reclassification of
dengue case definitions in the late 2000s [16] broadened the
spectrum of severe dengue to improve both the clinical recog-
nition of and surveillance for severe illness attributable to
DENV infection [21]. Nonetheless, dengue-related deaths
are still underrecognized in endemic areas due to reliance on
passive case reporting and/or review of death certificates to
identify fatal dengue cases, which may not be an accurate
means by which to capture dengue deaths due to frequent
misdiagnosis [12, 22–25].
On the opposite end of the clinical spectrum but far more
common than severe or fatal dengue, many mild illnesses
caused by DENV infection that do not conform to existing
dengue case definitions are neither diagnosed clinically nor
reported. Pediatric AFI surveillance in Ratchaburi, Thailand,
demonstrated that more than half of patients with symptomatic
DENV infection had an undifferentiated fever that did not
meet the WHO dengue case definition [26, 27]. Similar ob-
servations regarding the lack of sensitivity of the WHO den-
gue case definition in capturing individuals with symptomatic
DENV infection were made during active surveillance for
febrile illness in rural Thailand [28]. These findings are not
specific to Southeast Asia. In Nicaragua, one quarter of pedi-
atric patients with febrile illness had laboratory-confirmed
DENV infection but did not meet the WHO dengue case def-
inition [29]. Because these children were enrolled in a pro-
spective cohort study that assessed for both DENV infection
and dengue, these events in many cases would not otherwise
have been identified since asymptomatic and sub-clinical in-
fections would not have come to the attention of the health
care system. Thus, even in endemic areas where dengue
awareness is high in both the public and clinical communities,
DENV infection is underrecognized as a cause of mild illness,
thereby contributing to underestimation of the global burden
of illness caused by DENV infection.
The recognition of DENV infection as a cause of mild
illness has in part been made possible through improved mo-
lecular [30, 31] and serologic [32] diagnostic methods that
together enable accurate diagnosis with a single serum speci-
men. Of similar utility, particularly in areas without laborato-
ries capable of performing RT-PCR and ELISA, is the recent
availability of dengue rapid diagnostic tests (RDT) [32].
Consequently, dengue has now been detected in nearly all
regions of the tropics and sub-tropics (Fig. 1), including coun-
tries thought to have endemic dengue but where illness is still
unrecognized [33]. For example, dengue has long been
neglected in sub-Saharan Africa [34–37], and in the southern
USAwhere dengue is reemerging [38–40].
A necessary first step to better identify populations
most affected by dengue worldwide is improving clinical
awareness of dengue in the context of other etiologies of
AFI. Many tropical AFIs (e.g., chikungunya, Zika, lepto-
spirosis, influenza, scrub typhus, typhoid fever, bacterial
sepsis, West Nile virus infection, acute HIV infection)
share symptoms with dengue which complicates diagno-
sis. This challenge was demonstrated during a dengue
outbreak in 2011 among African Union Mission peace-
keeping troops in Mogadishu, Somalia, initially diagnosed
as an outbreak of “hemorrhagic malaria” (CDC, unpub-
lished data). Similar examples of underecognition of den-
gue in sub-Saharan Africa have recently come to light
[36, 41–43]. Even in areas where dengue has been endem-
ic for decades and burden of illness is well-recognized,
deficiencies persist in clinical diagnosis and management
of dengue patients [44, 45•]. Despite recent inroads, in-
cluding use of rapid diagnostic tests to identify dengue
outbreaks [46], improving the awareness and diagnosis
of dengue in Africa and other areas of the tropics where
dengue is neglected or underrecognized remains difficult
due to low clinical suspicion of dengue as a cause of non-
hemorrhagic AFI.
The consequence of underrecognition of DENV infec-
tion as a cause of mild illness is underestimation of the
economic and health-associated burden of dengue world-
wide [47]. Underreporting is an inherent facet of all pas-
sive surveillance systems, which are used for national
reporting of dengue cases in all countries worldwide that
capture such information. Enhanced surveillance in
Thailand [48], Nicaragua [49], and Puerto Rico [50], all
of which are countries where dengue has been endemic
for decades and clinical awareness is high, has estimated
underreporting of dengue through national surveillance to
be between 8- and 28-fold. Underreporting of dengue in
countries with non-endemic travel-associated dengue is
likely to be higher than in endemic areas due to low clin-
ical awareness, lack of availability of diagnostics, and/or
inefficient infrastructure for surveillance to operate. For
example, roughly 80% of >5800 laboratory-positive den-
gue cases in the USA were not reported during 2008–
2011(CDC, unpublished data). A further consequence of
underrecognition is delayed or ineffective control re-
sponses. In Thailand, vector control activities that are trig-
gered by reported dengue cases overlooked more than half
of individuals with symptomatic DENV infection since
the cases did not meet reporting requirements [26].
Therefore, timely initiation of population-level interven-
tions to control or limit DENV transmission relies on the
following: (1) clinical recognition of dengue as a potential
cause of the patient’s illness, (2) availability of timely and
accurate laboratory diagnostics to differentiate DENV in-
fection from other AFIs, and (3) appropriate case
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definitions and surveillance mechanisms to enable nation-
al case reporting.
Dengue in Adults
The traditional view in Southeast Asia is that dengue is a
pediatric illness that rarely affects adults if at all [17].
Because much of our understanding of dengue pathogenesis
originated in the Southeast Asia outbreaks of DHF, this view
has pervaded the perception of dengue worldwide.
Consequently, most surveillance for dengue in Southeast
Asia was conducted primarily in pediatric hospitals where
DHF cases are predominantly reported [17]. For example, in
Cambodia, only hospitalized persons aged <15 years were
reported, a trend that persists in the present day [48].
Although the burden of dengue in Southeast Asia is unargu-
ably highest in children and adolescents, contemporaneous
study of dengue in adults in Indonesia demonstrated a larger
burden of disease than previously realized [51]. Similarly,
enhanced surveillance for dengue in Vietnam demonstrated
that adult dengue patients account for one third of all
dengue-related hospital admissions [52]. Population-based
dengue surveillance conducted in Brazil [53], Puerto Rico
[54], Malaysia [55], and Taiwan [56] demonstrated that half
or more of all reported dengue cases are in adults who expe-
rience the full spectrum of clinical illness. Although the age
groups most affected by dengue and severe dengue may in-
deed differ between Southeast Asia and the Americas, due at
least in part to differences in the relative force of infection [57,
58], lack of population-based surveillance precludes compar-
ison of these potential differences in affected age groups.
Therefore, population-based surveillance for dengue should
be implemented and reporting restrictions that only allow pe-
diatric cases to be reported as suspected dengue cases should
be removed. Only through these approaches can age groups
affected by dengue be accurately identified and compared
between countries.
Such comparisons are necessary to better understand the
outcome of DENV infection between different age groups.
Infection with a DENV has long been thought to be more
likely to result in clinically manifest dengue in adults than in
children, and recent studies have examined this finding in
more detail. Studies from Brazil [59] and Vietnam [60] have
demonstrated that the risk of developing dengue after first
DENV infection increases with age. Similarly, studies in
Brazil [61], Puerto Rico [62], Thailand [63], and Taiwan
[56] have shown that illness severity correlates with age in
individuals with clinically apparent dengue; however, these
observations are contrary to those seen in Singapore [64].
This discrepancy is not easily resolved, as recent clinical eval-
uations of potential differences in dengue manifestations be-
tween children and adults conducted in Nicaragua [65],
Thailand [63, 66], and Vietnam [67] have demonstrated that
children more frequently develop vascular leakage and shock
whereas adults have a propensity to experience hemorrhage
and organ involvement. Although tempting to conclude that
age-dependent differences in the response to DENV infection
are responsible for differential disease manifestations between
children and adults, the possibility of other explanations such
as adults having underlying co-morbidities, co-infections, de-
layed presentation for care, and/or delayed recognition of den-
gue by health care providers [22, 23, 64, 68] cannot be ex-
cluded as possible explanations for these observed differ-
ences. Further investigation is therefore needed to determine
if adults more frequently experience severe illness following
DENV infection and/or illness onset, or if the manifestations
of dengue and severe dengue are simply disparate in children
and adults.
Recent findings from Thailand have demonstrated that the
median age of reported dengue case patients has increased
over the past decade [69]. Although several explanations for
this phenomenon have been proposed, including decreased
vector abundance [70], a more plausible explanation is that a
demographic shift in the age structure of Thailand due to a
decreasing birth rate and increasing immigration led to a de-
creased force of infection and a consequent increase in age of
DHF cases [71]. Interestingly, these changes occurred in the
context of a decreasing force of DENV transmission while the
basic reproductive number was unchanged, further suggesting
that the expanding age groups affected by dengue was due
more to underlying changes in the demographics of the pop-
ulation than with changes in the dynamics of DENV transmis-
sion [58]. Should similar observations of increasing age of
dengue patients be made in other countries, further elucidation
of the mechanisms responsible will be needed to determine if
this age shift is due to demographic or other changes.
Neurologic Manifestions of DENV Infection
A number of investigators have documented that DENVs,
while apparently less neurotropic than other flaviviruses
such as Japanese encephalitis virus, West Nile virus, St.
Louis encephalitis virus, and now Zika virus, cause a rela-
tively small but significant burden of neurologic illness [72].
Neurologic manifestations include encephalopathy, encepha-
litis, and neuromuscular abnormalities. The incidence of
dengue with neurologic complications and the proportion
of febrile neurologic illness due to DENV infection varies
markedly (4–47%) in reports from different settings [73].
Involvement of the central nervous system is now a criterion
for severe dengue; however, standardized diagnostic criteria
for neurologic manifestations of dengue are lacking [74].
Again, increased clinical awareness and systematic testing
for dengue in patients with acute febrile neurologic illness
using standardized clinical definitions are necessary for a
clearer understanding of disease burden.
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Mechanisms of DENV Dissemination
Dengue epidemics typically occur every 3–5 years in endemic
areas, and peak dengue incidence typically occurs in associa-
tion with the rainy season during both epidemic and non-
epidemic years [16]. Although several studies have associated
the occurrence of dengue epidemics with El Niño southern
oscillation (ENSO), ENSO does not independently determine
the occurrence of epidemics [75]. The identification of accu-
rate predictors of when epidemics will occur [76] has been
complicated by the integral role played by mosquito popula-
tions in DENV spread; the existence of four antigenically
distinct DENV types, all of which have different dynamics
of infection and replication within mosquitoes and humans;
and the relative contributions of homo- and heterotypic
DENV immunity to herd immunity.
An established risk factor for DENV infection is sharing
living space with a person with dengue [77–79], and as such
dengue cases typically cluster at the household and neighbor-
hood levels in both urban [80, 81] and rural [82, 83] settings.
Mapping the travel patterns of dengue case-patients in Peru
revealed that DENV transmission within communities is at-
tributable more to mobility of infected humans than to infect-
ed mosquitoes [81], which have limited flight range and do
not frequently mediate transmission outside of the household
[84]. Interestingly, recent studies have revealed that a similar,
but mechanistically distinct, perspective can be applied on a
larger scale and may in part explain the periodicity of epi-
demics. Cummings and colleagues elegantly demonstrated
that Bangkok, Thailand frequently serves as a dengue epicen-
ter, from which a wave of dengue travels in humans away
from Bangkok roughly every 3 years at ~148 km per month
to ultimately affect nearly the entire country [85]. Similar ob-
servations implicating cities as the site of spread of epidemics
have since been made in Vietnam [86, 87] and Brazil [88].
Because the introduction of new DENV clades is one factor
associated with the occurrence of epidemics [89, 90] and
changes in disease severity [91], a more complete understand-
ing of whether new clades arise in cities or if cities serve to
amplify new clades after they are introduced, or both, will
assist in the planning of dengue control efforts.
Similar to inter-city spread of DENVs, a well-recognized
mechanism of intercontinental DENV spread is via infected
travelers returning from endemic areas [92]. A prospective
study of more than 1200 short-term Dutch travelers to the
tropics demonstrated that 14.6 DENV infections occurred
per 1000 person-months of travel [93]. Similarly, risk of
DENV infection was predicted to be 0.17 and 0.2% for a 1-
week stay during peak dengue season in Singapore [94] and
Thailand [95], respectively, which correlates well with rates
observed in Israeli travelers to Thailand [96]. However, attack
rates can be considerably higher during short-term travel to
regions with endemic dengue among certain high risk groups.
For example, 25% of a cohort of American missionaries ex-
perienced symptomatic DENV infection following a 1-week
trip to Haiti during a presumptive epidemic [97]. Risk of
DENV infection and likelihood of importation to travelers’
home countries varies by duration of stay, the environments
encountered during travel (e.g., vacation travel to a resort ver-
sus visiting friends and family in an urban area), and intensity
of DENV transmission when travel occurs (e.g., peak versus
low dengue season) [98].
Hundreds of viremic travelers each year return to areas of
the USA and Europe that have Aedesmosquitoes and a largely
susceptible human population [99], demonstrating that trav-
elers are at risk not only of becoming ill following DENV
infection while abroad, but also of importing the virus and
causing local outbreaks, as has recently occurred in the USA
[100–102] and Europe [103]. Moreover, dengue epidemics in
Taiwan [104] and China [105] have been associated with
DENV importation from Southeast Asia, whereas those in
Queensland, Australia, were associated with importation from
Oceania [106, 107]. These findings together reinforce that
travel-associated dengue cases can introduce and result in lo-
cal DENV transmission, illustrating the need for improved
clinical awareness and reporting of travel-associated dengue
cases to implement public health measures to contain
outbreaks.
New Views on DENVAntibodies
The presence of anti-DENVantibodies that bind the virus but
do not neutralize it to prevent infection of new cells is a well-
established risk factor for developing severe dengue [16].
However, in relation to protecting both individuals from de-
veloping dengue and populations from experiencing epi-
demics, the role of DENV immunity until recently had been
largely neglected. Early studies of heterotypic immunity con-
ducted by Albert Sabin demonstrated that cross-protection
against disease following infection with a DENV type differ-
ent from the initial infecting type lasts several months [108].
However, contemporaneous cohort studies conducted in
Nicaragua [109] and Thailand [110] estimated the duration
of protective heterotypic immunity to be on the order of 1 to
3 years and demonstrated a directly proportional relationship
between duration of time between infections and likelihood of
developing symptomatic infection. Although the correlation
of the duration of protective heterotypic antibody with the
frequency of epidemics is interesting [111], the relationship
between waning heterotypic antibody and its effect upon herd
immunity has yet to be conclusively addressed. Finally, stud-
ies from Nicaragua and Puerto Rico have provided limited
evidence for a sex-specific difference in the duration of pro-
tective heterotypic immunity [109, 112], a finding which re-
mains to be more rigorously validated.
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The same longitudinal cohort studies have shed new light
on the frequency and role of homotypic DENV immunity.
Though DENV infection was historically considered to result
in sterilizing immunity against the infecting DENV type [108,
113], re-infection with the same DENV type has been recently
documented, albeit rarely, in individuals in Nicaragua, Peru,
and Puerto Rico [112, 114•, 115••]. Of interest, most
homotypic DENV infections identified to date have been se-
quential infections with DENV-2, which was recently shown
to be the most antigenically diverse of the four DENVs [2].
Since most homotypic DENV infections appear to have been
either asymptomatic or subclinical, the relative contribution of
homotypic DENVre-infection on burden of disease is unclear.
Nonetheless, a natural history study of human DENV infec-
tions in Cambodia elegantly demonstrated that asymptomatic
DENV infections do indeed lead to infection of mosquitos
[116•]. Therefore, even if homotypic infections do not appre-
ciably increase the burden of disease, they still may contribute
to propagation of transmission. Although such homotypic in-
fections have been rarely identified to date, it is indeed possi-
ble that they occur more often than has been previously ap-
preciated but are only now being recognized due to the recent
initiation of dengue cohort studies, improved case detection
through enhanced or more efficient case surveillance, and/or
increased use of molecular diagnostic techniques that can
identify the infecting DENV type with greater reliability than
serologic diagnosis [113].
Similarly, the occurrence of asymptomatic DENV infec-
tions and the role that antibodies play in the likelihood of
developing symptomatic infection have recently been ad-
dressed. In Thailand, the wide yearly fluctuation between the
ratio of symptomatic-to-inapparent (rS:I) DENV infections in
school children in a given year is related to DENV infections
in the previous year, in that the prior year’s incidence and
subsequent year’s rS:I DENV infections have an inverse rela-
tionship [117]. Similar observations were made utilizing data
from a prospective pediatric cohort in Nicaragua [109], where
neutralizing antibody titers were observed to be a correlate of
protection against symptomatic DENV infection [118•].
Although Sabin demonstrated that pre-existing antibodies
against Japanese encephalitis virus (JEV), a flavivirus genet-
ically related to DENV, protected individuals from developing
dengue following DENV infection [108], in a recent school-
based cohort from Thailand pre-existing anti-JEV antibody
increased the likelihood of symptomatic DENV infection
[119]. Conversely, the absence of clinically apparent illness
due to infection with West Nile virus, also a flavivirus, despite
circulation in sentinel animals in areas with endemic dengue
[120, 121] suggests that anti-DENV antibodies may provide
some level of protection from WNV disease. Future studies
should continue to address the role of cross-reactive anti-fla-
vivirus antibodies in the potential modulation of clinical out-
come following infection with DENV or another flavivirus,
including a potentially worsened clinical outcome as has been
suggested by a case report of an individual who had been
previously infected with a DENVand died from hemorrhagic
illness following WNV infection [122].
Conclusions
Although we now know more about dengue than ever before,
much work remains before a comprehensive understanding of
the modern epidemiology of dengue can be achieved. In ad-
dition, despite more than a century of research, still no effec-
tive means to prevent dengue in communities is available.
Until such a solution is found, the worldwide burden of den-
gue is likely to continue to increase.
Despite recent advances in dengue vaccines [123, 124] and
novel approaches to vector control [125], challenges in both
fields [126, 127] have left optimization of patient management
through increased clinical awareness as the only approach to
reduce dengue-related mortality [45•]. To effectively measure
the effect of interventions on the incidence and burden of
dengue, as well as to consistently define the occurrence of
epidemics, baseline surveillance data that are gathered equiv-
alently throughout the world is urgently needed [128].
Moreover, implementing enhanced surveillance (i.e., sentinel
health care facilities in which clinicians are trained and en-
couraged on how to appropriately identify, manage, and report
dengue patients) in areas with existing passive surveillance
systems will enable calculation of accurate rates of dengue
and severe dengue, and allow for inter- and intra-country com-
parison of the burden due to dengue [19, 128].
A persistent limitation to understanding the burden of den-
gue is reporting of dengue cases to public health authorities. In
the absence of consistent case reporting, an accurate under-
standing of the epidemiology of dengue will be difficult to
achieve. An additional benefit to complementing passive sur-
veillance with a limited number of enhanced surveillance sites
is therefore to gain a more accurate estimate of the morbidity
and mortality due to dengue. Implementation of enhanced
surveillance sites will therefore better enable an accurate esti-
mation of the burden of severe and fatal dengue. Furthermore,
to improve case identification, availability of dengue diagnos-
tics, both rapid tests and laboratory-based confirmatory test-
ing, is needed to differentiate patients with dengue from other
AFIs, and thus additional emphasis should be placed on im-
proved dengue laboratory capacity worldwide, but especially
in areas where dengue is neglected. Finally, without country-
specific knowledge of all age groups affected by dengue, the
required evidence for countries to identify the age groups that
should receive a dengue vaccine is both insufficient and con-
voluted. Periodic population-based serosurveys can and will
be useful for this purpose but are logistically challenging and
labor intensive. Enhanced surveillance is the most feasible
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route to gain an accurate, comprehensive, and comparable
understanding of the global epidemiology of dengue.
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